41X.F Ardelyx Inc

Healthcare Biotechnology Frankfurt Exchange
2.66 EUR
Close of Nov 12, 2026
2.53 6.75
Market cap
EUR 669M
P/E
-
P/B
4.45x
ROE
-44.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 41X.F undervalued?

Graham number

The Graham number of Ardelyx Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ardelyx Inc fundamental analysis

No fundamental analysis for Ardelyx Inc yet.

Ardelyx Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ardelyx Inc

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name…

Full company profile